Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Emanuel Della-Torre and Lorenzo Dagna.
Emanuel Della-Torre
Connection Strength
6.719
Lorenzo Dagna
  1. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
    View in: PubMed
    Score: 0.943
  2. Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al' by Cheng and Zhang. Ann Rheum Dis. 2020 Aug 19.
    View in: PubMed
    Score: 0.898
  3. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
    View in: PubMed
    Score: 0.895
  4. Intrathecal rituximab for IgG4-related hypertrophic pachymeningitis. J Neurol Neurosurg Psychiatry. 2018 04; 89(4):441-444.
    View in: PubMed
    Score: 0.729
  5. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
    View in: PubMed
    Score: 0.232
  6. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020; 11:598308.
    View in: PubMed
    Score: 0.230
  7. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvasc Res. 2021 01; 133:104071.
    View in: PubMed
    Score: 0.226
  8. Mavrilimumab for severe COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Nov; 2(11):e662-e663.
    View in: PubMed
    Score: 0.225
  9. Systemic lupus erythematosus and COVID-19: what we know so far. Ann Rheum Dis. 2020 Aug 28.
    View in: PubMed
    Score: 0.225
  10. Colchicine treatment in community healthcare setting to prevent severe COVID-19. Ann Rheum Dis. 2020 Aug 27.
    View in: PubMed
    Score: 0.225
  11. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
    View in: PubMed
    Score: 0.223
  12. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
    View in: PubMed
    Score: 0.222
  13. Treating COVID-19 with colchicine in community healthcare setting. Clin Immunol. 2020 08; 217:108490.
    View in: PubMed
    Score: 0.221
  14. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
    View in: PubMed
    Score: 0.220
  15. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. Clin Exp Rheumatol. 2019 May-Jun; 37 Suppl 118(3):159-166.
    View in: PubMed
    Score: 0.201
  16. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. Arthritis Res Ther. 2018 10 03; 20(1):222.
    View in: PubMed
    Score: 0.197
  17. A CD8a- Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. Arthritis Rheumatol. 2018 07; 70(7):1133-1143.
    View in: PubMed
    Score: 0.192
  18. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford). 2017 12 01; 56(12):2084-2092.
    View in: PubMed
    Score: 0.186
  19. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'. Ann Rheum Dis. 2021 Oct; 80(10):e159.
    View in: PubMed
    Score: 0.059
  20. Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. Clin Microbiol Infect. 2021 08; 27(8):1190-1192.
    View in: PubMed
    Score: 0.059
  21. COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. Semin Arthritis Rheum. 2020 10; 50(5):1150-1157.
    View in: PubMed
    Score: 0.056
  22. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.